MCID: LCL006
MIFTS: 66

Localized Scleroderma

Categories: Rare diseases, Skin diseases, Genetic diseases, Bone diseases, Respiratory diseases, Nephrological diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 12 49 55 36 14 69
Morphea 12 49 51 69
Localized Fibrosing Scleroderma 49 55
Scleroderma, Circumscribed or Localized 12
Unspecified Circumscribed Scleroderma 12
Localized Scleroderma [ambiguous] 12
Circumscribed Scleroderma Nos 12
Circumscribed Scleroderma 12
Scleroderma, Localized 49
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

55
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 55  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
ICD10 32 L94.0
ICD9CM 34 701.0
MeSH 41 D012594
NCIt 46 C72069
Orphanet 55 ORPHA90289
MESH via Orphanet 42 D012594
UMLS via Orphanet 70 C0036420
ICD10 via Orphanet 33 L94.0
KEGG 36 H01493

Summaries for Localized Scleroderma

NIH Rare Diseases : 49 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, localized scleroderma is serious and disabling. There are two generally recognized types of localized scleroderma: morphea and linear.   Last updated: 4/3/2012

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to systemic scleroderma and scleroderma, familial progressive, and has symptoms including hyperpigmentation of the skin, hypopigmentation of the skin and cigarette-paper scars. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Vaccines and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone, and related phenotypes are growth/size/body region and cellular

Wikipedia : 72 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 systemic scleroderma 32.6 CTGF SELE TGFB1
2 scleroderma, familial progressive 30.7 BMP6 CTGF
3 fasciitis 29.9 BMP6 IL6 TNF
4 central nervous system vasculitis 29.6 IL6 TNF
5 keloids 29.5 DCN MMP1 SMAD3 TGFB1
6 arthritis 29.1 IL6 MMP1 MMP13 TNF
7 rheumatoid arthritis 28.7 IL6 MMP1 MMP13 TGFB1 TNF
8 linear scleroderma 11.4
9 atrophoderma of pierini and pasini 11.1
10 fibromatosis, gingival, 1 10.5 MMP1 TGFB1
11 tendinopathy 10.5 DCN MMP1
12 periodontitis, chronic 10.4 IL6 MMP1
13 diabetic foot ulcers 10.4 IL6 TGFB1
14 tuberculoid leprosy 10.4 BMP6 TGFB1
15 immune suppression 10.4 BMP6 IL6
16 peyronie disease 10.4 SMAD3 TGFB1
17 stiff skin syndrome 10.3 CTGF TGFB1
18 kashin-beck disease 10.3 MMP1 TNF
19 beryllium disease 10.3 TGFB1 TNF
20 scorpion envenomation 10.3 IL6 TNF
21 anthracosis 10.3 BMP6 TNF
22 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
23 critical limb ischemia 10.3 IL6 TNF
24 clonorchiasis 10.3 TGFB1 TNF
25 dupuytren contracture 10.3 BMP6 DCN TGFB1
26 streptococcal toxic-shock syndrome 10.3 IL6 TNF
27 null-cell leukemia 10.2 IL6 TNF
28 arteriovenous fistula 10.2 IL6 SELE
29 crouzon syndrome 10.2 BMP6 DCN TGFB1
30 retinitis pigmentosa 55 10.2 IL6 TNF
31 preterm premature rupture of the membranes 10.2 IL6 MMP1
32 funisitis 10.2 IL6 SELE
33 glossitis 10.2 IL6 TNF
34 nontuberculous mycobacterial lung disease 10.2 BMP6 TNF
35 anterior uveitis 10.2 IL6 TNF
36 reynolds syndrome 10.2
37 hypertrophic scars 10.2 BMP6 SMAD3 TGFB1
38 acute vascular insufficiency of intestine 10.2 IL6 TNF
39 penile disease 10.2 DCN SMAD3 TGFB1
40 peyronie's disease 10.2 DCN SMAD3 TGFB1
41 poems syndrome 10.2 IL6 TNF
42 cholecystolithiasis 10.2 BMP6 CTGF TGFB1
43 gingival fibromatosis 10.2 CTGF MMP1 TGFB1
44 microscopic colitis 10.2 IL6 TNF
45 meconium aspiration syndrome 10.2 IL6 TNF
46 burning mouth syndrome 10.2 IL6 TNF
47 chronic active epstein-barr virus infection 10.1 SELE TGFB1
48 osteosclerotic myeloma 10.1 IL6 TNF
49 stachybotrys chartarum 10.1 IL6 TNF
50 scleritis 10.1 SELE TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

55 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperpigmentation of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0000953
2 hypopigmentation of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0001010
3 cigarette-paper scars 55 31 hallmark (90%) Very frequent (99-80%) HP:0001073
4 split hand 55 31 occasional (7.5%) Occasional (29-5%) HP:0001171
5 arthralgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002829
6 skeletal muscle atrophy 55 31 frequent (33%) Frequent (79-30%) HP:0003202
7 scarring alopecia of scalp 55 31 occasional (7.5%) Occasional (29-5%) HP:0004552
8 flexion contracture of toe 55 31 occasional (7.5%) Occasional (29-5%) HP:0005830
9 stiff skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0030053
10 hemiatrophy of lower limb 55 31 occasional (7.5%) Occasional (29-5%) HP:0100557
11 hemiatrophy of upper limb 55 31 occasional (7.5%) Occasional (29-5%) HP:0100558
12 lipoatrophy 55 31 occasional (7.5%) Occasional (29-5%) HP:0100578
13 myalgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003326
14 dermal atrophy 55 Very frequent (99-80%)
15 hemiatrophy 55 Occasional (29-5%)
16 flexion contracture 55 Occasional (29-5%)

UMLS symptoms related to Localized Scleroderma:


pruritus, exanthema

MGI Mouse Phenotypes related to Localized Scleroderma:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.09 SMAD3 IL6 BMP6 CTGF MMP13 SELE
2 cellular MP:0005384 10.08 DCN IL6 MMP13 CTGF SELE TNF
3 homeostasis/metabolism MP:0005376 10.06 SMAD3 IL6 MMP1 MMP13 CTGF SELE
4 cardiovascular system MP:0005385 10.04 IL6 MMP13 CTGF SELE TNF SMAD3
5 integument MP:0010771 9.97 IL6 CTGF MMP13 SELE DCN SMAD3
6 digestive/alimentary MP:0005381 9.93 SMAD3 IL6 CTGF DCN TGFB1 TNF
7 liver/biliary system MP:0005370 9.8 SMAD3 IL6 CTGF SELE TGFB1 TNF
8 neoplasm MP:0002006 9.73 SMAD3 IL6 MMP1 DCN TGFB1 TNF
9 respiratory system MP:0005388 9.63 IL6 CTGF SELE DCN TGFB1 TNF
10 skeleton MP:0005390 9.56 SMAD3 IL6 BMP6 CTGF MMP13 DCN
11 vision/eye MP:0005391 9.17 SMAD3 IL6 CTGF SELE DCN TGFB1

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
5
Acetylcholine Approved Phase 3 51-84-3 187
6
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
7
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
8
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
11
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
12
Alginic acid Approved, Experimental, Investigational Phase 3 9005-32-7
13
Glucosamine Approved, Investigational, Nutraceutical Phase 2, Phase 3 3416-24-8 439213
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
15 Antirheumatic Agents Phase 3,Phase 2,Phase 1
16 insulin Phase 3
17 Sildenafil Citrate Phase 3 171599-83-0
18 interferons Phase 3,Phase 1
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 abobotulinumtoxinA Phase 3
21 Fibrinolytic Agents Phase 2, Phase 3
22 Central Nervous System Depressants Phase 2, Phase 3
23 Adjuvants, Immunologic Phase 3
24 Chelating Agents Phase 3
25 Sodium Channel Blockers Phase 2, Phase 3
26 Cholinergic Agents Phase 3
27 Neuromuscular Agents Phase 3
28 Gastrointestinal Agents Phase 3
29 Coagulants Phase 3,Phase 1
30 Neurotransmitter Agents Phase 3
31 Glucuronyl glucosamine glycan sulfate Phase 2, Phase 3
32 Hemostatics Phase 3,Phase 1
33 Anesthetics Phase 2, Phase 3
34 Vasodilator Agents Phase 3,Phase 2
35 onabotulinumtoxinA Phase 3
36 Anesthetics, Local Phase 2, Phase 3
37 Diuretics, Potassium Sparing Phase 2, Phase 3
38 Antacids Phase 3
39 Dopamine Agents Phase 3
40 Dopamine Antagonists Phase 3
41 Peripheral Nervous System Agents Phase 2, Phase 3, Phase 1
42 Anti-Arrhythmia Agents Phase 2, Phase 3
43 Endothelin Receptor Antagonists Phase 2, Phase 3
44 Anticoagulants Phase 2, Phase 3, Phase 1
45 Hypoglycemic Agents Phase 2, Phase 3
46 Pharmaceutical Solutions Phase 2, Phase 3
47 Hypolipidemic Agents Phase 2, Phase 3
48 Antiemetics Phase 3
49 Phosphodiesterase 5 Inhibitors Phase 3
50 Phosphodiesterase Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 83)

# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
3 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
4 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
5 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
6 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
7 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
8 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
9 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
10 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
11 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
12 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
13 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
14 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2 Rituximab
15 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2 imatinib mesylate
16 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
17 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
18 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
19 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
20 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2 standard of care
21 IL1-TRAP, Rilonacept, in Systemic Sclerosis Completed NCT01538719 Phase 1, Phase 2 Rilonacept
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2 Abatacept;Placebo
23 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
24 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
25 Zibotentan Better Renal Scleroderma Outcome Study Completed NCT02047708 Phase 2 Zibotentan
26 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
27 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
28 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
29 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
30 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
31 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
32 Riociguat in Scleroderma Associated Digital Ulcers Recruiting NCT02915835 Phase 2 Riociguat;Placebo
33 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
34 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Not yet recruiting NCT03351114 Phase 2 Crisaborole
35 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Not yet recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
36 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
37 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2 Bosentan;Placebo
38 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
39 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546
40 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Recruiting NCT02426229 Phase 1 dabigatran etexilate
41 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
42 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
43 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897
44 Genetic Variants in Linear Localized Scleroderma Unknown status NCT02222038
45 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174
46 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890
47 Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Completed NCT00812188
48 The CARRA Registry Completed NCT01697254
49 UVA1 Light for Treatment of Scleroderma and Similar Conditions Completed NCT00476801
50 The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy Completed NCT03141125

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

38
Skin, Lung, Bone, Endothelial, Bone Marrow, Breast, Skeletal Muscle

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 380)
# Title Authors Year
1
Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. ( 29077971 )
2018
2
Impact of a new simplified disability scoring system for adult patients with localized scleroderma. ( 29369402 )
2018
3
Abatacept Improves Skin-score and Reduces Lesions in Patients with Localized Scleroderma: A Case Series. ( 29313055 )
2018
4
Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. ( 28271552 )
2017
5
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
6
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 29173689 )
2017
7
Evaluation of mean platelet volume in localized scleroderma. ( 29166498 )
2017
8
Systemic sclerosis complicated with localized scleroderma-like lesions induced by KAPbner phenomenon. ( 29279288 )
2017
9
Quantitative Assessment of Skin Stiffness in Localized Scleroderma Using Ultrasound Shear-Wave Elastography. ( 28457631 )
2017
10
Periostin in Mature Stage Localized Scleroderma. ( 28566901 )
2017
11
Surgical Management of Localized Scleroderma. ( 29090197 )
2017
12
The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. ( 27943304 )
2017
13
Musculoskeletal MRI findings of juvenile localized scleroderma. ( 28091699 )
2017
14
Thrombocytopenia Associated with Localized Scleroderma: Report of Four Pediatric Cases and Review of the Literature. ( 28543515 )
2017
15
Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. ( 29136260 )
2017
16
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. ( 28792092 )
2017
17
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 27693175 )
2016
18
A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. ( 27401109 )
2016
19
BILATERAL CHOROIDAL EXCAVATION IN JUVENILE LOCALIZED SCLERODERMA. ( 27533641 )
2016
20
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. ( 27696700 )
2016
21
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma:A a clinical and immunohistochemical randomized controlled study. ( 27510285 )
2016
22
Localized scleroderma en coup de sabre in the Neurology Clinic. ( 27456882 )
2016
23
Is Localized Scleroderma Caused by Borrelia burgdorferi? ( 27387068 )
2016
24
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. ( 27700194 )
2016
25
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. ( 26138783 )
2016
26
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. ( 26582717 )
2016
27
Localized Scleroderma: A Clinical Review. ( 27604889 )
2016
28
Oxidative stress parameters in localized scleroderma patients. ( 27591994 )
2016
29
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. ( 26577237 )
2016
30
Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. ( 26983450 )
2016
31
German guidelines for the diagnosis and therapy of localized scleroderma. ( 26819124 )
2016
32
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. ( 27274545 )
2016
33
Lichen sclerosus associated with localized scleroderma: dermoscopy contribution. ( 27579757 )
2016
34
Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. ( 26985179 )
2016
35
Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome. ( 27154452 )
2016
36
Measurement of transepidermal water loss in localized scleroderma. ( 26970329 )
2016
37
Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. ( 25923607 )
2015
38
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. ( 26254121 )
2015
39
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. ( 26161155 )
2015
40
Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. ( 25888470 )
2015
41
Systemic involvement in localized scleroderma/morphea. ( 26321403 )
2015
42
Localized Scleroderma Presenting as Port-wine Stains: Report of Two Cases and a Literature Review. ( 25791763 )
2015
43
Recurrence rates in localized scleroderma (morphoea). ( 25776242 )
2015
44
Localized Scleroderma of Lower Extremities:Clinical and Magnetic Resonance Imaging Features. ( 26564453 )
2015
45
Localized scleroderma: clinical spectrum and therapeutic update. ( 25672301 )
2015
46
Durometry as an Outcome Measure in Juvenile Localized Scleroderma. ( 26302039 )
2015
47
Juvenile localized scleroderma with port wine stain: coincidental or possible common pathogenetic association. ( 25814757 )
2015
48
The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. ( 26559172 )
2015
49
Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma. ( 25582037 )
2015
50
Co-existence of Lichen Sclerosus and Localized Scleroderma in Female Monozygotic Twins. ( 24841519 )
2014

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 BMP6 CTGF IL6 MMP1 MMP13 SMAD3
2
Show member pathways
13.43 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
3
Show member pathways
13.18 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
4 12.75 IL6 MMP1 SMAD3 TGFB1
5
Show member pathways
12.66 DCN MMP1 MMP13 TGFB1
6
Show member pathways
12.57 BMP6 CTGF IL6 TGFB1 TNF
7
Show member pathways
12.51 IL6 SMAD3 TGFB1 TNF
8
Show member pathways
12.49 MMP1 MMP13 SMAD3 TGFB1
9
Show member pathways
12.48 IL6 SMAD3 TGFB1 TNF
10
Show member pathways
12.44 IL6 SMAD3 TGFB1 TNF
11 12.34 IL6 SMAD3 TGFB1 TNF
12
Show member pathways
12.23 IL6 MMP1 MMP13 TNF
13
Show member pathways
12.15 MMP1 SELE TGFB1
14 12.15 IL6 TGFB1 TNF
15
Show member pathways
12.13 IL6 TGFB1 TNF
16 12.13 BMP6 CTGF SMAD3 TGFB1
17 12.09 IL6 SMAD3 TGFB1
18
Show member pathways
12.05 IL6 SMAD3 TGFB1
19 12.04 BMP6 CTGF SMAD3 TGFB1
20
Show member pathways
12.02 IL6 SMAD3 TGFB1
21 12 MMP1 SMAD3 TGFB1
22 11.98 BMP6 SMAD3 TGFB1
23 11.95 IL6 TGFB1 TNF
24 11.94 IL6 MMP1 SMAD3 TGFB1 TNF
25 11.92 IL6 SMAD3 TGFB1 TNF
26 11.89 IL6 SELE TNF
27 11.88 IL6 SMAD3 TGFB1
28
Show member pathways
11.87 IL6 TGFB1 TNF
29
Show member pathways
11.84 MMP1 MMP13 TNF
30 11.84 IL6 MMP1 TGFB1 TNF
31 11.82 IL6 TGFB1 TNF
32
Show member pathways
11.8 IL6 SMAD3 TGFB1
33
Show member pathways
11.79 IL6 SMAD3 TGFB1
34 11.74 BMP6 DCN IL6 TGFB1
35 11.73 IL6 MMP1 SELE
36 11.69 IL6 MMP1 TGFB1 TNF
37 11.68 IL6 TGFB1 TNF
38 11.62 IL6 TGFB1 TNF
39 11.61 BMP6 MMP13 TGFB1
40 11.54 SMAD3 TGFB1 TNF
41 11.5 CTGF IL6 TGFB1 TNF
42 11.48 CTGF SMAD3 TGFB1
43
Show member pathways
11.47 IL6 MMP1 SELE TNF
44 11.44 CTGF IL6 TNF
45 11.41 IL6 SMAD3 TNF
46 11.35 IL6 SELE SMAD3 TGFB1 TNF
47 11.27 IL6 MMP1 SMAD3 TGFB1
48 11.26 IL6 SELE TNF
49 11.23 DCN IL6 MMP1
50 11.16 IL6 TGFB1 TNF

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.62 DCN MMP1 MMP13 TGFB1
2 extracellular region GO:0005576 9.61 BMP6 CTGF DCN DEFB1 IL6 MMP1
3 proteinaceous extracellular matrix GO:0005578 9.55 CTGF DCN MMP1 MMP13 TGFB1
4 Golgi lumen GO:0005796 9.43 DCN DEFB1 TGFB1
5 extracellular space GO:0005615 9.28 BMP6 CTGF DCN DEFB1 IL6 MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 BMP6 DEFB1 IL6 SMAD3 TNF
2 regulation of receptor activity GO:0010469 9.88 BMP6 CTGF IL6 TGFB1 TNF
3 aging GO:0007568 9.85 CTGF DCN TGFB1
4 leukocyte migration GO:0050900 9.84 MMP1 SELE TGFB1 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.83 CTGF TGFB1 TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 IL6 TGFB1 TNF
7 inflammatory response GO:0006954 9.8 BMP6 IL6 SELE TGFB1 TNF
8 defense response to Gram-positive bacterium GO:0050830 9.79 DEFB1 IL6 TNF
9 wound healing GO:0042060 9.79 DCN SMAD3 TGFB1
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.77 IL6 TGFB1 TNF
11 positive regulation of gene expression GO:0010628 9.77 CTGF IL6 SMAD3 TGFB1 TNF
12 extracellular matrix disassembly GO:0022617 9.76 DCN MMP1 MMP13
13 response to glucocorticoid GO:0051384 9.75 BMP6 IL6 TNF
14 SMAD protein signal transduction GO:0060395 9.73 BMP6 SMAD3 TGFB1
15 protein import into nucleus, translocation GO:0000060 9.68 TGFB1 TNF
16 endochondral ossification GO:0001958 9.68 BMP6 MMP13
17 positive regulation of collagen biosynthetic process GO:0032967 9.67 CTGF TGFB1
18 positive regulation of protein complex assembly GO:0031334 9.67 TGFB1 TNF
19 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.66 SMAD3 TGFB1
20 cell-cell junction organization GO:0045216 9.66 SMAD3 TGFB1
21 negative regulation of myoblast differentiation GO:0045662 9.65 TGFB1 TNF
22 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.65 SMAD3 TGFB1
23 positive regulation of chemokine production GO:0032722 9.64 IL6 TNF
24 positive regulation of chondrocyte differentiation GO:0032332 9.64 BMP6 SMAD3
25 leukocyte tethering or rolling GO:0050901 9.63 SELE TNF
26 extrinsic apoptotic signaling pathway GO:0097191 9.63 SMAD3 TGFB1 TNF
27 lens fiber cell differentiation GO:0070306 9.62 SMAD3 TGFB1
28 negative regulation of lipid storage GO:0010888 9.61 IL6 TNF
29 SMAD protein complex assembly GO:0007183 9.6 SMAD3 TGFB1
30 regulation of striated muscle tissue development GO:0016202 9.55 SMAD3 TGFB1
31 regulation of binding GO:0051098 9.51 SMAD3 TGFB1
32 positive regulation of bone mineralization GO:0030501 9.5 BMP6 SMAD3 TGFB1
33 positive regulation of extracellular matrix assembly GO:1901203 9.49 SMAD3 TGFB1
34 positive regulation of mononuclear cell migration GO:0071677 9.43 TGFB1 TNF
35 negative regulation of mitotic cell cycle GO:0045930 9.43 SMAD3 TGFB1 TNF
36 evasion or tolerance of host defenses by virus GO:0019049 9.16 SMAD3 TGFB1
37 positive regulation of SMAD protein import into nucleus GO:0060391 9.13 BMP6 SMAD3 TGFB1
38 negative regulation of fat cell differentiation GO:0045599 8.92 IL6 SMAD3 TGFB1 TNF
39 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 BMP6 DCN IL6 SMAD3 TGFB1 TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 BMP6 IL6 TGFB1 TNF
2 collagen binding GO:0005518 9.43 DCN MMP13 SMAD3
3 transforming growth factor beta receptor binding GO:0005160 9.13 BMP6 SMAD3 TGFB1
4 growth factor activity GO:0008083 8.92 BMP6 CTGF IL6 TGFB1

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....